Showing 1 - 7 of 7
Patient-reported outcome measures (PROMs) are now routinely collected in the English National Health Service (NHS) and used to compare and reward hospital performance within a high-powered pay-for-performance scheme. However, PROMs are prone to missing data. For example, hospitals often fail to...
Persistent link: https://www.econbiz.de/10010857126
Context Until recently, purchasers’ options regarding whether to pay for the use of technologies have been binary in nature: a treatment is covered or not covered. However, policies have emerged which expand the options - for example, linking coverage to evidence development, an option...
Persistent link: https://www.econbiz.de/10011133794
A study by health economists at the University of York has, for the first time, produced an estimate of the impact on other NHS patients of new and more costly drugs and other treatments. This research suggests a refinement of the way the National Institute for Health and Clinical Excellence...
Persistent link: https://www.econbiz.de/10010857127
This paper reviews studies providing evidence of the cost-effectiveness of safe motherhood interventions in low-income countries. The economic case for investing in safe motherhood interventions is also examined. It is estimated that 1,600 women die globally each day as a result of problems...
Persistent link: https://www.econbiz.de/10005344334
It is imperative that health care resources are spent as efficiently as possible by committing them to demonstrably cost-effective treatments and procedures. The NHS reforms of 1989 aimed to help achieve this by separating out the roles of purchaser and provider. In doing so, ‘trade’ between...
Persistent link: https://www.econbiz.de/10005344402
Pharmaceutical prescribing currently represents around 10% of total National Health Service expenditure, and is one of the most inflationary elements of spending (Parliamentary Office of Science and Technology 1993). Between 1980 and 1990, the overall cost of a prescription increased by 19%....
Persistent link: https://www.econbiz.de/10005344452
Background: The National Institute for Health and Care Excellence (NICE) emphasises that cost-effectiveness is not the only consideration in health technology appraisal and is increasingly explicit about other factors considered relevant. Observing NICE decisions and the evidence considered in...
Persistent link: https://www.econbiz.de/10011133797